nach oben

Erschienen in:

01.04.2018 | Non-clinical study

Postmarketing modifications to cancer drug labelling in US

Erschienen in: Reactions Weekly | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Excerpt

In the US, cancer drug indications not initially supported by data from RCTs¹ are associated with more postmarketing safety-related label modifications. …

RCTs = randomised controlled trials

Shepshelovich D, et al. Postmarketing Modifications of Drug Labels for Cancer Drugs Approved by the US Food and Drug Administration Between 2006 and 2016 With and Without Supporting Randomized Controlled Trials. Journal of Clinical Oncology : [8 pages], 11 Apr 2018. Available from: URL: http://dx.doi.org/10.1200/JCO.2017.77.5593

Titel: Postmarketing modifications to cancer drug labelling in US
Publikationsdatum: 01.04.2018
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2018
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-018-44956-7

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Postmarketing modifications to cancer drug labelling in US

Excerpt

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2018

Lenalidomide/thalidomide

Lenvatinib

Certolizumab pegol: no teratogenic effect in pregnant women

Allopurinol/fluorouracil/folinic acid/oxaliplatin

Multiple drugs

Multiple drugs